Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for AMYVID
- B-amyloid as a Marker for GBM Bioimaging
- Plasma P-tau2017 and Quantitative Amyloid PET Imaging
- Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
- Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
- MRI and PET Biomarkers for Cognitive Decline in Older Adults
- Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy
- Flortaucipir PET Imaging in Subjects With FTD
- The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis
- Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations
- Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials
- Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
- Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
- Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
- Florbetapir Calibration to the Centiloid Scale
- The Feasibility of Florbetapir Quantitation in Europe
- Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
- 18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy
- Evaluation of Reader Training Processes
- Imaging Characteristics of a Follow-up 18F-AV-1451 Scan
- A Study of Gantenerumab in Participants With Mild Alzheimer Disease
- Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians
- Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
- The Feasibility of Florbetapir Quantitation
- Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
- Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.
- Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
- Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
- Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography
- A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
- A Study of Florbetapir (18F) in Japanese Healthy Volunteers
- A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
- A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers
- A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers
- A Study of 18F-AV-45 in Healthy Volunteers
- Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
- Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
- Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients
- Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
- A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Clinical trials list
click for details